Skip to main content
padlock icon - secure page this page is secure

Open Access Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma

Download Article:
(HTML 58.6 kb)
(PDF 1,484.2 kb)
Chordomas are rare tumors of the spine and skull base that are locally destructive and resistant to chemotherapy and radiation therapy, with a poor prognosis and limited therapeutic options. Chordoma patients have a long life expectancy with high mortality from the disease. Cancer stem cells, which are known to exist in chordomas, have extensive proliferative and self-renewal potential and are responsible for maintaining tumor heterogeneity along with chemotherapy and radiotherapy resistance. Leukemia inhibitory factor (LIF) has multiple functions in stem cell biology, the immune response, and cancer, and is potentially a key molecule that allows cancer stem cells to self-renew. The purpose of this study was to determine whether LIF increases the aggressive traits of chordoma cells and leads to a poor prognosis in patients. Chordoma cell lines were treated with LIF, and functional tests were done. Twenty skull base chordoma samples were checked for levels of LIF and a correlation with clinicopathological features. The whole transcriptome microarray was used to observe changes in gene expression. We observed increased migration, invasion, tumorosphere formation, colony formation, epithelial‐mesenchymal transition, and chemoresistance accompanied by a dramatic elevation in inflammatory gene networks and pathways in chordomas. The expression of LIF was associated with tumor size and a poorer overall survival. Microarray and quantitative real-time polymerase chain reaction assessments suggest that LIF can facilitate tumor-promoting inflammation. Results indicate that LIF plays a role in maintaining cancer stem cells in chordomas.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: Chordoma; Leukemia inhibitory factor (LIF); Prognosis; Tumor inflammation

Document Type: Research Article

Affiliations: 1: Department of Medical Genetics, Yeditepe University Medical School, Istanbul, Turkey 2: Department of Nanoscience and Nanoengineering, Institute of Science Ataturk University, Erzurum, Turkey 3: Department of Biotechnology, Institute of Science, Yeditepe University, Istanbul, Turkey 4: Department of Neurosurgery, Yeditepe University Medical School, Yeditepe University, Istanbul, Turkey 5: Department of Medical Pathology, Yeditepe University Medical School, Yeditepe University, Istanbul, Turkey

Publication date: August 7, 2017

This article was made available online on February 28, 2017 as a Fast Track article with title: "Leukemia Inhibitory Factor Promotes Aggressiveness of Chordoma".

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.

    From Volume 23, Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics is Open Access under the terms of the Creative Commons CC BY-NC-ND license.

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more